Thermo Fisher Scientific Inc. $TMO Shares Sold by Janus Henderson Group PLC

Janus Henderson Group PLC lessened its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 11.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,096,959 shares of the medical research company’s stock after selling 140,903 shares during the period. Janus Henderson Group PLC’s holdings in Thermo Fisher Scientific were worth $635,635,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of TMO. J. Stern & Co. LLP raised its position in shares of Thermo Fisher Scientific by 58,006.4% in the fourth quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company’s stock valued at $18,258,082,000 after buying an additional 31,455,105 shares during the last quarter. Norges Bank acquired a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at approximately $3,072,744,000. Wellington Management Group LLP grew its holdings in Thermo Fisher Scientific by 88.9% in the third quarter. Wellington Management Group LLP now owns 2,699,460 shares of the medical research company’s stock valued at $1,309,292,000 after purchasing an additional 1,270,191 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in Thermo Fisher Scientific by 19.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,701,353 shares of the medical research company’s stock valued at $4,462,550,000 after purchasing an additional 1,230,872 shares during the period. Finally, Franklin Resources Inc. grew its holdings in Thermo Fisher Scientific by 21.0% in the third quarter. Franklin Resources Inc. now owns 5,925,671 shares of the medical research company’s stock valued at $2,874,069,000 after purchasing an additional 1,028,125 shares during the period. Institutional investors and hedge funds own 89.23% of the company’s stock.

Wall Street Analysts Forecast Growth

TMO has been the subject of a number of recent analyst reports. Stifel Nicolaus lowered their target price on shares of Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating for the company in a report on Friday, April 24th. Weiss Ratings restated a “hold (c)” rating on shares of Thermo Fisher Scientific in a report on Wednesday, April 8th. Jefferies Financial Group upgraded shares of Thermo Fisher Scientific to a “strong-buy” rating in a report on Friday, April 24th. HSBC downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and lowered their target price for the company from $670.00 to $540.00 in a report on Wednesday, June 3rd. Finally, Royal Bank Of Canada set a $490.00 target price on shares of Thermo Fisher Scientific and gave the company a “sector perform” rating in a report on Thursday, May 14th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $608.95.

Thermo Fisher Scientific Price Performance

TMO opened at $460.62 on Thursday. The company has a quick ratio of 1.15, a current ratio of 1.53 and a debt-to-equity ratio of 0.77. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $643.99. The company has a 50 day moving average of $477.80 and a two-hundred day moving average of $524.61. The company has a market cap of $171.18 billion, a P/E ratio of 25.32, a P/E/G ratio of 2.09 and a beta of 0.88.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The company had revenue of $11.01 billion during the quarter, compared to the consensus estimate of $10.86 billion. During the same period in the previous year, the firm earned $5.15 earnings per share. Thermo Fisher Scientific’s revenue for the quarter was up 6.2% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, analysts expect that Thermo Fisher Scientific Inc. will post 24.85 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 15th. Shareholders of record on Monday, June 15th will be paid a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 0.4%. The ex-dividend date is Monday, June 15th. Thermo Fisher Scientific’s payout ratio is currently 10.34%.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, COO Gianluca Pettiti sold 400 shares of the company’s stock in a transaction on Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the transaction, the chief operating officer directly owned 25,051 shares in the company, valued at approximately $11,590,095.66. This represents a 1.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.